These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27881095)

  • 1. A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis.
    Alroughani R; Deleu D; El Salem K; Al-Hashel J; Alexander KJ; Abdelrazek MA; Aljishi A; Alkhaboori J; Al Azri F; Al Zadjali N; Hbahbih M; Sokrab TE; Said M; Rovira À
    BMC Neurol; 2016 Nov; 16(1):240. PubMed ID: 27881095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between brain volume loss and disability in multiple sclerosis: A systematic review.
    Matthews PM; Gupta D; Mittal D; Bai W; Scalfari A; Pollock KG; Sharma V; Hill N
    Mult Scler Relat Disord; 2023 Jun; 74():104714. PubMed ID: 37068369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain volume loss in multiple sclerosis is independent of disease activity and might be prevented by early disease-modifying therapy.
    Slezáková D; Kadlic P; Jezberová M; Boleková V; Valkovič P; Minar M
    Neurol Neurochir Pol; 2023; 57(3):282-288. PubMed ID: 37144903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity.
    Yokote H; Kamata T; Toru S; Sanjo N; Yokota T
    Neurol Sci; 2018 Oct; 39(10):1713-1716. PubMed ID: 29974307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of brain volume measures in multiple sclerosis.
    De Stefano N; Airas L; Grigoriadis N; Mattle HP; O'Riordan J; Oreja-Guevara C; Sellebjerg F; Stankoff B; Walczak A; Wiendl H; Kieseier BC
    CNS Drugs; 2014 Feb; 28(2):147-56. PubMed ID: 24446248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis.
    Andorra M; Nakamura K; Lampert EJ; Pulido-Valdeolivas I; Zubizarreta I; Llufriu S; Martinez-Heras E; Sola-Valls N; Sepulveda M; Tercero-Uribe A; Blanco Y; Saiz A; Villoslada P; Martinez-Lapiscina EH
    JAMA Neurol; 2018 Oct; 75(10):1246-1255. PubMed ID: 29971335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis.
    Janardhan V; Bakshi R
    Arch Neurol; 2000 Oct; 57(10):1485-91. PubMed ID: 11030802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy.
    Damasceno A; Damasceno BP; Cendes F
    Mult Scler; 2016 Jan; 22(1):64-72. PubMed ID: 26432855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
    Kappos L; De Stefano N; Freedman MS; Cree BA; Radue EW; Sprenger T; Sormani MP; Smith T; Häring DA; Piani Meier D; Tomic D
    Mult Scler; 2016 Sep; 22(10):1297-305. PubMed ID: 26585439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
    Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
    Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice.
    Sastre-Garriga J; Pareto D; Battaglini M; Rocca MA; Ciccarelli O; Enzinger C; Wuerfel J; Sormani MP; Barkhof F; Yousry TA; De Stefano N; Tintoré M; Filippi M; Gasperini C; Kappos L; Río J; Frederiksen J; Palace J; Vrenken H; Montalban X; Rovira À;
    Nat Rev Neurol; 2020 Mar; 16(3):171-182. PubMed ID: 32094485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis.
    Uher T; Krasensky J; Sobisek L; Seidl Z; Bergsland N; Dwyer MG; Kubala Havrdova E; Zivadinov R; Horakova D; Vaneckova M
    J Neuroimaging; 2018 May; 28(3):328-337. PubMed ID: 29485230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of the relationships between regional grey matter atrophy and cognition in multiple sclerosis.
    Nocentini U; Bozzali M; Spanò B; Cercignani M; Serra L; Basile B; Mannu R; Caltagirone C; De Luca J
    Brain Imaging Behav; 2014 Sep; 8(3):378-86. PubMed ID: 22584774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.
    Vollmer T; Huynh L; Kelley C; Galebach P; Signorovitch J; DiBernardo A; Sasane R
    Neurol Sci; 2016 Feb; 37(2):165-79. PubMed ID: 26537494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain atrophy and cognitive impairment in multiple sclerosis: a review.
    Lanz M; Hahn HK; Hildebrandt H
    J Neurol; 2007 May; 254 Suppl 2():II43-8. PubMed ID: 17503128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "No evidence of disease activity": Is it an aspirational therapeutic goal in multiple sclerosis?
    Mayssam EN; Eid C; Khoury SJ; Hannoun S
    Mult Scler Relat Disord; 2020 May; 40():101935. PubMed ID: 31951861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between neurofilament light chain levels, disease activity and brain atrophy in progressive multiple sclerosis.
    Szilasiova J; Mikula P; Rosenberger J; Fedicova M; Urban P; Frigova L; Vitkova M; Gdovinova Z; Hanes J; Stevens E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep; 166(3):304-311. PubMed ID: 34092793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis.
    Uher T; Krasensky J; Malpas C; Bergsland N; Dwyer MG; Kubala Havrdova E; Vaneckova M; Horakova D; Zivadinov R; Kalincik T
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33727311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis.
    Sastre-Garriga J; Arévalo MJ; Renom M; Alonso J; González I; Galán I; Montalban X; Rovira A
    J Neurol Sci; 2009 Jul; 282(1-2):120-4. PubMed ID: 19157420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis.
    Anderson VM; Fox NC; Miller DH
    J Magn Reson Imaging; 2006 May; 23(5):605-18. PubMed ID: 16596564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.